Walid Abi-Saab Sells 45,000 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the sale, the insider directly owned 169,669 shares in the company, valued at $4,251,905.14. The trade was a 20.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Walid Abi-Saab also recently made the following trade(s):

• On Wednesday, March 4th, Walid Abi-Saab sold 808 shares of uniQure stock. The stock was sold at an average price of $9.06, for a total transaction of $7,320.48.

uniQure Trading Up 0.2%

QURE opened at $29.17 on Thursday. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of -8.38 and a beta of 0.87. The company’s 50 day moving average price is $17.58 and its two-hundred day moving average price is $23.80.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. As a group, research analysts predict that uniQure N.V. will post -3.68 earnings per share for the current year.

Institutional Investors Weigh In On uniQure

Institutional investors have recently modified their holdings of the company. Torren Management LLC bought a new stake in shares of uniQure in the 4th quarter valued at $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the period. IFP Advisors Inc acquired a new position in shares of uniQure during the 4th quarter valued at $48,000. Smartleaf Asset Management LLC acquired a new position in shares of uniQure during the 4th quarter valued at $48,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the 3rd quarter valued at $50,000. 78.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on QURE. Wolfe Research initiated coverage on shares of uniQure in a report on Monday, February 23rd. They set a “peer perform” rating on the stock. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $11.00 to $35.00 in a research note on Monday, March 9th. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Finally, Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.